GRI-0621: Promising IPF Treatment with No Lung Function Decline
New IPF drug GRI-0621 shows no lung decline at 6 weeks and anti-fibrotic effects in early studies. It's safe and well-tolerated. This offers hope for IPF patients, as current treatments are limited. Full results expected Q3 2025.